158 related articles for article (PubMed ID: 20484887)
1. Oxidative stress in benign prostatic hyperplasia and prostate cancer.
Pace G; Di Massimo C; De Amicis D; Corbacelli C; Di Renzo L; Vicentini C; Miano L; Tozzi Ciancarelli MG
Urol Int; 2010; 85(3):328-33. PubMed ID: 20484887
[TBL] [Abstract][Full Text] [Related]
2. Oxidative stress and antioxidant status in non-metastatic prostate cancer and benign prostatic hyperplasia.
Aydin A; Arsova-Sarafinovska Z; Sayal A; Eken A; Erdem O; Erten K; Ozgök Y; Dimovski A
Clin Biochem; 2006 Feb; 39(2):176-9. PubMed ID: 16413012
[TBL] [Abstract][Full Text] [Related]
3. [Expressions of endothelin-1 in benign prostatic hyperplasia and prostate cancer and their significance].
Zhou WQ; Sun YH; Yin HL; Zhang ZY; Ge JP; Cheng W; Ma HQ; Wei W; Zhou SG; Ma HH; Gao JP
Zhonghua Nan Ke Xue; 2007 Aug; 13(8):685-9. PubMed ID: 17918704
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of serum protein-bound sialic acid in benign and malignant prostatic growth: possible role of oxidative stress in sialic acid homeostasis.
Goswami K; Nandeesha H; Koner BC; Nandakumar DN
Prostate Cancer Prostatic Dis; 2007; 10(4):356-9. PubMed ID: 17404581
[TBL] [Abstract][Full Text] [Related]
5. Oxidative stress parameters in patients with prostate cancer, benign prostatic hyperplasia and asymptomatic inflammatory prostatitis: A prospective controlled study.
Kaya E; Ozgok Y; Zor M; Eken A; Bedir S; Erdem O; Ebiloglu T; Ergin G
Adv Clin Exp Med; 2017 Oct; 26(7):1095-1099. PubMed ID: 29211357
[TBL] [Abstract][Full Text] [Related]
6. Increased oxidative/nitrosative stress and decreased antioxidant enzyme activities in prostate cancer.
Arsova-Sarafinovska Z; Eken A; Matevska N; Erdem O; Sayal A; Savaser A; Banev S; Petrovski D; Dzikova S; Georgiev V; Sikole A; Ozgök Y; Suturkova L; Dimovski AJ; Aydin A
Clin Biochem; 2009 Aug; 42(12):1228-35. PubMed ID: 19465015
[TBL] [Abstract][Full Text] [Related]
7. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
8. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
9. Phytoestrogen tissue levels in benign prostatic hyperplasia and prostate cancer and their association with prostatic diseases.
Brössner C; Petritsch K; Fink K; Auprich M; Madersbacher S; Adlercreutz H; Rehak P; Petritsch P
Urology; 2004 Oct; 64(4):707-11. PubMed ID: 15491706
[TBL] [Abstract][Full Text] [Related]
10. [Expression and its significance of b-FGF in human benign prostatic hyperplasia and prostatic carcinoma tissues].
Wang FL; Wang H; Qin WJ; Wu GJ; Zhang G; Li KN
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Mar; 20(2):203-5. PubMed ID: 15191726
[TBL] [Abstract][Full Text] [Related]
11. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
12. Oxidative stress and body composition in prostate cancer and benign prostatic hyperplasia patients.
Cimino S; Favilla V; Russo GI; Galvano F; Li Volti G; Barbagallo I; Giofrè SV; D'Orazio N; DI Rosa A; Madonia M; Morgia G
Anticancer Res; 2014 Sep; 34(9):5051-6. PubMed ID: 25202090
[TBL] [Abstract][Full Text] [Related]
13. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia.
Soulitzis N; Karyotis I; Delakas D; Spandidos DA
Int J Oncol; 2006 Aug; 29(2):305-14. PubMed ID: 16820871
[TBL] [Abstract][Full Text] [Related]
14. Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in benign prostatic hyperplasia and prostate cancer.
Stefanou D; Batistatou A; Kamina S; Arkoumani E; Papachristou DJ; Agnantis NJ
In Vivo; 2004; 18(2):155-60. PubMed ID: 15113042
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of the leptin and leptin receptor expressions in prostate tissues.
Hoon Kim J; Lee SY; Myung SC; Kim YS; Kim TH; Kim MK
Asian J Androl; 2008 Nov; 10(6):923-8. PubMed ID: 18958356
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of the differences in the expression of HSP27 and c-kit between benign prostatic hyperplasia and prostatic cancer tissues].
Zhen B; Shen Y; Zhang YM; Zhu CH; Liu ZL
Zhonghua Nan Ke Xue; 2006 May; 12(5):416-20. PubMed ID: 16755871
[TBL] [Abstract][Full Text] [Related]
17. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate.
Zhigang Z; Wenlu S
Prostate; 2008 Feb; 68(2):190-9. PubMed ID: 18076024
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer antigen-1 as a potential novel marker for prostate cancer.
Liu BQ; Wu YD; Li PH; Wei JX; Zhang T; Liu RL
Asian J Androl; 2007 Nov; 9(6):821-6. PubMed ID: 17968469
[TBL] [Abstract][Full Text] [Related]
19. Systemic stress responses in patients undergoing surgery for benign prostatic hyperplasia.
Ruzic B; Tomaskovic I; Trnski D; Kraus O; Bekavac-Beslin M; Vrkic N
BJU Int; 2005 Jan; 95(1):77-80. PubMed ID: 15638899
[TBL] [Abstract][Full Text] [Related]
20. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
